Seneca House Advisors’s Biolase, Inc. BIOL Stock Holding History

Seneca House Advisors’s Portfolio BIOL Stock Details BIOL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-4	Closed	-$9K	–	85
2021 Q1	$9K	Buy	+4	New	+$9.83K	0.01%	78

Other funds holding BIOL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Perkins Capital Management Wayzata, Minnesota $107M AUM 82.62% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Seneca House Advisors's BIOL Position: Q2 2021 in Review

Seneca House Advisors sold out of Biolase, Inc. (BIOL) in Q2 2021, closing a stake of 4 shares — an estimated $9K sold.

Seneca House Advisors first reported a position in BIOL in Q1 2021 and held it in 1 quarter. The position peaked at $9K in Q1 2021. 31 funds tracked by Wall St. Rank hold BIOL as of Q2 2021.

Seneca House Advisors reported no remaining Biolase, Inc. position as of Q2 2021 after selling out during the quarter.
Seneca House Advisors sold 4 Biolase, Inc. shares in Q2 2021, an estimated $9K.
Seneca House Advisors first reported a position in Biolase, Inc. in Q1 2021 and held it in 1 quarter.
Seneca House Advisors's Biolase, Inc. position peaked at $9K in Q1 2021.
31 funds tracked by Wall St. Rank held Biolase, Inc. as of Q2 2021.

Based on Seneca House Advisors's 13F filing for Q2 2021, filed 29 Jul 2021.